

Novel market mechanisms to spur innovation in AMR

Dr Akhil Bansal

- Doctor, Royal Free London NHS Trust
- Head, AMR Funding Circle (Supported by Schmidt Futures, University of Chicago)






Axes

- Stage of R&D
 - Pre-clinical
 - Early stage clinical
 - Late stage clinical
 - Market authorisation
 - Manufacturing and distribution
- Funding mechanisms
 - Push
 - Pull



Biomedical innovation from "bench to bedside"





Pull incentives - brief overview

- “Pull” funding rewards outputs and outcomes.
- They signal to firms there will be demand for socially useful innovations
- Generally not spent until the goals have been achieved.
- Examples- prizes, results-based financing, or advance market commitments
- Advantages
 - Open to all firms
 - Reward success
 - **Value based pricing**
 - User adoption is key
 - Co-payment from different sources



Pull incentives and AMR - there's history!

- Vaccines
 - Pneumococcal vaccine
 - COVID-19 vaccine
- New antimicrobials
 - NHS Subscription + proposals from Japan, Canada and Sweden
 - PASTEUR Act (proposed)
 - EU TTE extension (proposed)
- New diagnostics
 - Longitude Prize
 - NIH Prize



National Institutes of Health
Turning Discovery Into Health

Wednesday, August 5, 2020

Rapid diagnostic for gonorrhea wins \$19 million federal prize competition to combat antibiotic resistance

LONGITUDE PRIZE

<https://amr.longitudeprize.org/antibiotic-resistance/>

<https://www.nih.gov/news-events/news-releases/rapid-diagnostic-gonorrhea-wins-19-million-federal-prize-competition-combat-antibiotic-resistance>



Pull incentives for novel diagnostic tests

- Money
 - To de-risk that latter stages of diagnostic test development
 - Guaranteed market and revenue
 - Sources: government and philanthropic actors
- More than money
 - Involvement and demand from clinicians and healthcare systems.
 - Regulatory approval + regulatory approval across contexts
 - Procurement challenges



Next steps

Working to develop, and fund, an advance market commitment for **neonatal sepsis**

Ideally, a combination of push and pull (re: CARB-X)



Next steps

Working to develop, and fund, an advance market commitment for **neonatal sepsis**

Ideally, a combination of push and pull (re: CARB-X)

What I would benefit from:

- Expertise
- Funder and healthcare contacts (esp in SSA and India)
- Anything else that might be helpful